• Engineering Kitasamycin Biosynthesis via Leucine-Resistant M

  2026-06-02

  This study reveals how leucine analog-resistant mutants of Streptomyces kitasatoensis can be harnessed to selectively enhance the biosynthesis of the most potent kitasamycin (leucomycin) antibiotic components. By dissecting the regulatory controls of precursor supply, the work provides a foundational strategy for optimizing macrolide antibiotic production for translational inhibition and antibacterial studies.

• Tetrahedral DNA Frameworks Boost Enzymatic Oligonucleotide S

  2026-06-02

  A recent study demonstrates that using highly ordered tetrahedral DNA nanostructures as primer scaffolds significantly enhances the efficiency and fidelity of enzymatic oligonucleotide synthesis. This advancement addresses key limitations in enzyme accessibility and error rates, with major implications for DNA data storage and synthetic biology.

• Sodium Nitroprusside: Applied Workflows in Vascular Research

  2026-06-01

  Sodium Nitroprusside stands out as a nitric oxide donor for precise vascular smooth muscle relaxation and platelet function assays. This article delivers actionable workflow enhancements, troubleshooting insights, and highlights the translational impact of sex-specific hypertension modeling.

• Merbromin as a Selective Mixed-Type Inhibitor of SARS-CoV-2

  2026-06-01

  This study identifies merbromin as a selective and potent mixed-type inhibitor of the SARS-CoV-2 main protease (3CLpro), using high-throughput screening of ~6000 compounds. The findings clarify merbromin’s inhibition mechanism and provide a framework for rational antiviral drug design targeting coronavirus proteases.

• 5-Azacytidine in Translational Oncology: Mechanisms and Next

  2026-05-31

  This thought-leadership article explores the mechanistic landscape, translational promise, and strategic integration of 5-Azacytidine (5-AzaC) in epigenetic cancer research. By bridging recent discoveries in immune modulation, such as the restoration of viral mimicry in PTEN-deficient glioblastoma, with evidence-backed workflow guidance and product intelligence, the article empowers researchers to harness 5-AzaC's full potential while anticipating both limitations and future opportunities.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Tracking Delivery & Transla

  2026-05-30

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables dual-fluorescence tracking of mRNA delivery and protein translation in real time, accelerating workflow optimization for gene delivery research. Its immune-evasive and stability-enhanced design empowers robust, reproducible transfection studies in advanced nanoparticle formulations.

• EPI-001: Redefining Androgen Receptor Targeting in CRPC and

  2026-05-29

  Explore how EPI-001, a pioneering androgen receptor N-terminal domain inhibitor, advances research into castration-resistant prostate cancer (CRPC) and triple-negative breast cancer (TNBC). Gain unique insights into its mechanism, practical assay implications, and critical distinctions from other AR-targeted strategies.

• Ouabain: Selective Na+/K+-ATPase Inhibitor in Cardiovascular

  2026-05-29

  Ouabain is a potent, selective Na+/K+-ATPase inhibitor widely used to dissect ion transport and cardiac physiology. Its cell-impermeable nature and high affinity for the Na+/K+-ATPase enable precise, reproducible studies in cardiovascular and neurobiological models. APExBIO's B2270 formulation supports standardized protocols for translational research.

• WP1066, JAK2/STAT3 Inhibitor: Applied Workflows & Troublesho

  2026-05-28

  WP1066, a potent JAK2/STAT3 inhibitor from APExBIO, enables precision targeting of oncogenic and immunoregulatory pathways in cancer and regenerative research. This article delivers actionable protocols, comparative advantages, and troubleshooting strategies that maximize reproducibility and translational impact across tumor, hematologic, and bone repair models.

• Applied Research with Leptin (116-130), amide, mouse: Protoc

  2026-05-28

  Leptin (116-130), amide, mouse, empowers metabolic and immunometabolic research with its robust solubility and defined activity profile. Explore optimized workflows, troubleshooting insights, and translational applications that set this adipocyte-derived hormone fragment apart for obesity and diabetes studies.

• Ceruletide (SKU B8465): Reliable Modeling in Pancreatic Rese

  2026-05-27

  Ceruletide (SKU B8465) is a synthetic decapeptide widely adopted for reproducible modeling of pancreatic fibrosis and gastrointestinal function. This article addresses real laboratory scenarios—ranging from protocol optimization to vendor selection—demonstrating how Ceruletide's validated purity, solubility, and batch consistency support advanced cell-based and in vivo studies. Explore the practical workflow insights and evidence-backed parameter recommendations for maximizing assay reliability.

• Dual Inhibition: SN-38 Blocks FUBP1–FUSE Binding in Cancer C

  2026-05-27

  This study reveals that camptothecin and its analog SN-38, beyond their established role as topoisomerase I inhibitors, directly disrupt the binding of the oncoprotein FUBP1 to its DNA target sequence FUSE. These findings expand the mechanistic understanding of SN-38 in advanced cancer models and highlight a potential new avenue for targeting FUBP1-driven oncogenic pathways.

• Scenario-Driven Best Practices with DiscoveryProbe™ Bioactiv

  2026-05-26

  This article addresses laboratory challenges in cell viability, proliferation, and cytotoxicity assays by showcasing how DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) enables reproducible, high-throughput screening. Integrating workflow scenarios, literature-backed analysis, and protocol insights, it guides researchers to leverage SKU L1022P for robust target validation and pathway analysis.

• CCR5-Containing Extracellular Vesicles Drive RA Pathogenesis

  2026-05-26

  This study reveals that CCR5-positive extracellular vesicles (EVs) from synovial fibroblasts aggravate joint destruction in rheumatoid arthritis (RA) by activating NF-κB signaling. Targeted inhibition of CCR5, including encapsulation of the antagonist Maraviroc (UK-427857) in EVs, mitigates these effects, underscoring CCR5 as a promising therapeutic target and research focus in RA.

• Novobiocin Sodium: Aminocoumarin Antibiotic for DNA Replicat

  2026-05-25

  Novobiocin Sodium is a well-defined aminocoumarin antibiotic that inhibits bacterial DNA gyrase, blocking DNA replication and associated cellular processes. Its robust solubility profile and validated research applications make it a reference standard for metabolic enzyme protease and apoptosis signaling pathway research. APExBIO supplies this compound under SKU B1992 for research use only.

451 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page